Floatz logo

Dostarlimab

Colonic Neoplasms

GlaxoSmithKlinemonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Colonic Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
First Affiliated Hospital of Guangxi Medical University
Phase 4BBB
PROPOFOL
Hillel Yaffe Medical Center
Phase 4BB
Ertapenem
University of Ulm
Phase 4BB
Levoleucovorin
Asan Medical Center
Phase 2BB
Sevoflurane
Uppsala University
Phase 4BB

View all 50 →

Same molecule, other indications

Dostarlimab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Neoplasms, ColonDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →